Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $216.00 at Oppenheimer

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $200.00 to $216.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 53.51% from the stock’s previous close. […]

Related Keywords

New York ,United States ,Neurocrine Biosciences ,Ingrid Delaet ,Eric Benevich ,Neurocrine Biosciences Company Profile ,Goldman Sachs Group ,Cantor Fitzgerald ,Securities Exchange Commission ,Fintrust Capital Advisors ,Neurocrine Biosciences Inc ,Nasdaq ,Bluepath Capital Management ,Wells Fargo Company ,Asset Management One Co ,Get Free Report ,Exchange Commission ,Management One ,Trust Capital Advisors ,York State Teachers Retirement System ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Boost Price Target ,Oppenheimer Holdings Inc ,